These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27035492)

  • 1. Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.
    Scangos KW; Caton M; Newman WJ
    J Clin Psychopharmacol; 2016 Jun; 36(3):283-5. PubMed ID: 27035492
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.
    Wartelsteiner F; Hofer A
    J Clin Psychopharmacol; 2015 Aug; 35(4):474-5. PubMed ID: 26075490
    [No Abstract]   [Full Text] [Related]  

  • 3. Applying long-acting injectable antipsychotics in first-episode schizophrenia to achieve first remission.
    Liu CC; Chiang HL; Wu SY
    CNS Drugs; 2008; 22(3):257-8. PubMed ID: 18278979
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy.
    arap Mengech HN; Wazome EG
    East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guidelines for the use of second-generation long-acting antipsychotics].
    Jarema M; Wichniak A; Dudek D; Samochowiec J; Bieńkowski P; Rybakowski J
    Psychiatr Pol; 2015; 49(2):225-41. PubMed ID: 26093588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting injectable antipsychotics in early psychosis: a literature review.
    Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
    Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP
    J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.
    Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH
    Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
    Cañas F; Möller HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
    Castle DJ; Udristoiu T; Kim CY; Sarosi A; Pidrman V; Omar AN; Rosales JI; Melamed Y; Isik T; Karagianis J; Treuer T
    World J Biol Psychiatry; 2009; 10(1):43-53. PubMed ID: 19137460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation long-acting injectable antipsychotic agents: an overview.
    Drug Ther Bull; 2012 Sep; 50(9):102-5. PubMed ID: 22966099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.
    Langley-DeGroot M; Joshi Y; Lehman D; Rao S
    J Clin Psychopharmacol; 2016 Jun; 36(3):277-9. PubMed ID: 27043124
    [No Abstract]   [Full Text] [Related]  

  • 20. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
    Azorin JM
    Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.